Innate Immunotheraputics Limited
Our People
Investment
Clinical Trials
Lead Candidate
Adjuvant
Contact Us
Subscribe to our RSS News Feed
Subscribe to our RSS feed with the following link:
News
Press Releases, News and Media
Media
Research
Home
Biopharmaceutical product development
Our People
Meet the team behind the research programmes
Investment
Company profile and future investment plans
Clinical Trials
Current trials and trial objectives
Lead Candidate
MIS416 - immune modulating microparticle
Microparticle Platform
A unique therapeutic microparticle
Adjuvant
Novel vaccine adjuvant for cellular immunity
Contact Us
Contact Innate Immunotherapeutics, Auckland, New Zealand
Subscribe to our RSS Feed
Media
Media Press Releases
Articles:
11/11/2011:
Innate Immunotherapeutics Advances Progressive Multiple Sclerosis Study of MIS416
View Article.
18/09/2011:
NZ Shareholders Exempt Capital Gains Tax
View Article.
18/09/2011:
Ministry of Health Grants Innate Therapeutics License to Manufacture MIS416…
View Article.
18/09/2011:
Innate Therapeutics’ Novel Microparticle Immune Response Modifier Shows Broad Spectrum…
View Article.
18/09/2011:
Treatment of Multiple Sclerosis patent lodged
View Article.
18/09/2011:
Innate Therapeutics Receives Funding for Clinical Trial of Progressive Multiple…
View Article.
8/10/2010:
Innate Therapeutics Initiates Phase 2 Testing of MIS416 in Patients…
View Article.